Please login to the form below

Not currently logged in
Email:
Password:

Hikma

This page shows the latest Hikma news and features for those working in and with pharma, biotech and healthcare.

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic drugmakers that have already won approval for generic Zytiga from the FDA include Mylan, Teva and Hikma Pharma and – with the injunction denied – there is nothing to stop them from

Latest news

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • The human perspective The human perspective

    Chief among these moves were the German company's exit from the generics business, via a $2.6bn deal with specialty firm Hikma, and its forthcoming asset swap with Sanofi.

  • Deal Watch table for May 2014 Deal Watch table for May 2014

    348. Bedford Labs (Boehringer Ingelheim) / Hikma. Asset / product acquisition.

  • Pharma deals during May 2014 Pharma deals during May 2014

    Hikma, the Jordanian generic company, acquired the assets of the US-based Bedford Labs (owned by Boehringer Ingelheim), a generic injectable manufacturer, for $300m (16 x sales). The price consists of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Hikma Pharmaceuticals appoints VP, sales and marketing, Generics. Kristy Ronco has been appointed as vice president, sales and marketing, generics for Hikma Pharmaceuticals. ... Ronco joins Hikma after more than a decade at Zydus Pharmaceuticals, where

  • Sigurdur Olafsson becomes CEO of Hikma Sigurdur Olafsson becomes CEO of Hikma

    As chief executive officer, Olafsson will take responsibility for the effective development and execution of Hikma’s corporate strategy, focusing on opportunities to accelerate growth of the global business. ... Said Darwazah, Hikma’s recently

  • Hikma appoints group scientific officer and global head of R&D Hikma appoints group scientific officer and global head of R&D

    Dr Surendera Tyagi joins the pharma group from Fresenius Kabi. Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr ... Surendera Tyagi, who will focus on the group’s non-injectables

More from appointments
Approximately 3 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics